Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Research ID

hum0163-v1Release info

This page is a past version (v1). The latest version is v3.
Latest version (v3)

Research title

Pharmacogenomics research for therapeutics in psychiatry, neurology and oncology

Research overview

Aims
Identification of biomarkers associated with efficacy and adverse drug reactions in therapeutics for psychiatric/neurological disorders or cancers, leading to establishment of stratified medicine based on pharmacogenomic information.
Methods
DNA/plasma samples and clinical information are collected from patients with psychiatric/neurological disorders or cancers. Targeted NGS analysis focusing on 100 pharmacogenes, HLA typing, metabolome analysis, and pharmacokinetic analysis were conducted to identify biomarkers associated with drug responses.
Participants/materials
Patients receiving psychotropic drugs (lamotrigine and clozapine), and patients receiving anti-cancer molecular targeted drugs (regorafenib, trastuzumab and nivolumab)
90 bullous pemphigoid cases; 737 general populations derived from Epstein-Barr virus-transformed B-lymphoblast cell lines of unrelated Japanese individuals established by the Pharma SNP Consortium (PSC)
URL
N/A

Datasets

The list is the one this version published; each dataset's content is shown as it is now.

CartDataset IDType of dataAnalysis methodAccess criteriaDate published
NHA000076NGS (Target Capture)
  • Targeted DNA sequencing
Unrestricted-access2018-12-14

Data provider

Principal investigator
Taisei Mushiroda
Affiliation
RIKEN Center for Integrative Medical Sciences, Laboratory for Pharmacogenomics

Research projects

No research projects.

Grants

NameTitleProject number
Advanced Genome Research and Bioinformatics Study to Facilitate Medical Innovation (GRIFIN), Platform Program for Promotion of Genome Medicine, Japan Agency for Medical Research and Development (AMED)
Pharmacogenomics research for therapeutics in psychiatry, neurology and oncology
  • JP16km0405201
Practical Research Project for Rare / Intractable Diseases
Elucidation of the pathogenesis and risk factors of bullous pemphigoid
  • JP22ek0109430

Related publications

TitleDOIDataset ID
GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes.
https://doi.org/10.18632/oncotarget.25712 (opens in a new tab)
Association of Genetic Variants of HLA-DQA1 with Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors
https://doi.org/10.1016/j.jid.2023.04.017 (opens in a new tab)